SEC Comment Letter for Dogwood Therapeutics, Inc. (DWTX) (CIK 0001818844) (DWTX) — Mar 23, 2022
Dogwood Therapeutics, Inc. (DWTX) (CIK 0001818844)
Date: March 23, 2022 · CIK: 0001818844 · Accession: 0000000000-22-003165
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-263700
Letter
United States securities and exchange commission logo March 23, 2022 Greg Duncan Chief Executive Officer Virios Therapeutics, Inc. 44 Milton Avenue Alpharetta, GA 30009 Re:Virios Therapeutics, Inc. Registration Statement on Form S-3 Filed March 18, 2022 File No. 333-263700 Dear Mr. Duncan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Margaret Schwartz at 202-551-7153 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Darrick M. Mix, Esq.
Show Raw Text
United States securities and exchange commission logo
March 23, 2022
Greg Duncan
Chief Executive Officer
Virios Therapeutics, Inc.
44 Milton Avenue
Alpharetta, GA 30009
Re:Virios Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 18, 2022
File No. 333-263700
Dear Mr. Duncan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Margaret Schwartz at 202-551-7153 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Darrick M. Mix, Esq.